Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | PREP | P48147 | 1/20 | 0.35 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.35 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL408851 | 0.92 | GPR119 (0.36) | CHRM2CHRM1CHRM3CHRNB2CHRNA4 | |
| SCHEMBL669989 | 0.81 | CHRM2 (0.44) | CHRM2CHRM1CHRM3CHRNB2CHRNA4 | |
| SCHEMBL8299717 | 0.81 | CHRM2 (0.44) | CHRM2CHRM1CHRM3CHRNB2CHRNA4 | |
| SCHEMBL1721264 | 0.78 | GPR119 (0.48) | CHRM2CHRM1CHRM3CHRNB2CHRNA4 | |
| SCHEMBL408852 | 0.76 | GPR119 (0.36) | CHRM2CHRM1CHRM3CHRNB2CHRNA4 | |
| SCHEMBL17075349 | 0.75 | GPR119 (0.43) | CHRM2CHRM1CHRM3CHRNB2CHRNA4 | |
| Iodide SCHEMBL17075351 | 0.74 | EIF2AK4 (0.39) | CHRM2CHRM1CHRM3CHRNB2CHRNA4 | |
| Iodide SCHEMBL14675890 | 0.74 | EIF2AK4 (0.39) | CHRM2CHRM1CHRM3CHRNB2CHRNA4 | |
| SCHEMBL16777487 | 0.73 | CHRM2 (0.42) | CHRM2CHRM1CHRM3CHRNB2CHRNA4 | |
| SCHEMBL1723133 | 0.73 | CHRM2 (0.41) | CHRM2CHRM1CHRM3CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120020881-A1 | Triaryl-sulphonium compounds, kit and methods for labeling positron emitting isotopes | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120020881-A1 | Triaryl-sulphonium compounds, kit and methods for labeling positron emitting isotopes | KIT, STS, TST | CHRM2 4114/4885CHRM1 3894/4885CHRM3 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.